McMurray, John J.V.

Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study

Stewart, S., Hart, C. L., Hole, D. J., & McMurray, J. J. V. (2001) · Heart

Atrial Fibrillation Management and OutcomesCardiovascular and Diving-Related Complications

Cited by 661

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

Teerlink, J. R., Diaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-Sørensen, T., et al. (2021) · New England Journal of Medicine

Heart Failure Treatment and ManagementCardiomyopathy and Myosin Studies

Cited by 656

Iron deficiency: an ominous sign in patients with systolic chronic heart failure

Jankowska, E. A., Rozentryt, P., Witkowska, A., Nowak, J., Hartmann, O., Ponikowska, B., Borodulin-Nadzieja, L., Banasiak, W., Polonski, L., Filippatos, G., et al. (2010) · European Heart Journal

Erythropoietin and Anemia TreatmentIron Metabolism and Disorders

Cited by 652

Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK

Stewart, S., Murphy, N., Walker, A., McGuire, A., & McMurray, J. J. V. (2004) · Heart

Atrial Fibrillation Management and OutcomesHealth Systems, Economic Evaluations, Quality of Life

Cited by 590

Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction

Olsson, L. G., Swedberg, K., Ducharme, A., Granger, C. B., Michelson, E. L., McMurray, J. J. V., Puu, M., Yusuf, S., & Pfeffer, M. A. (2006) · Journal of the American College of Cardiology

Atrial Fibrillation Management and OutcomesHeart Failure Treatment and Management

Cited by 574

Expert consensus document on ?-adrenergic receptor blockersThe Task Force on Beta-Blockers of the European Society of Cardiology

Lopez-Sendon, J. L., Swedberg, K. B., McMurray, J. J. V., Tamargo, J. L., Maggioni, A. P., Dargie, H., Tendera, M., Waagstein, F., Kjekshus, J., Lechat, P. P., et al. (2004) · European Heart Journal

Clinical practice guidelines implementationBlood Pressure and Hypertension Studies

Cited by 557

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

Wheeler, D. C., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Toto, R. D., et al. (2021) · The Lancet Diabetes & Endocrinology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 556

Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

Solomon, S. D., Vaduganathan, M., L. Claggett, B., Packer, M., Zile, M., Swedberg, K., Rouleau, J., A. Pfeffer, M., Desai, A., H. Lund, L., et al. (2020) · Circulation

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 551

Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology

Jaarsma, T., Beattie, J. M., Ryder, M., Rutten, F. H., McDonagh, T., Mohacsi, P., Murray, S. A., Grodzicki, T., Bergh, I., Metra, M., et al. (2009) · European Journal of Heart Failure

Palliative Care and End-of-Life IssuesHeart Failure Treatment and Management

Cited by 542

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

Petrie, M. C., Verma, S., Docherty, K. F., Inzucchi, S. E., Anand, I., Belohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., et al. (2020) · JAMA

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 531

Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction

Zile, M. R., Gottdiener, J. S., Hetzel, S. J., McMurray, J. J., Komajda, M., McKelvie, R., Baicu, C. F., Massie, B. M., & Carson, P. E. (2011) · Circulation

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 517

Why do SGLT2 inhibitors reduce heart failure hospitalization? Adifferential volume regulation hypothesis

Hallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. J. V., & Boulton, D. W. (2018) · Diabetes, Obesity and Metabolism

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 499

Erythropoietic response and outcomes in kidney disease and type 2 diabetes

Solomon, S. D., Uno, H., Lewis, E. F., Eckardt, K.-U., Lin, J., Burdmann, E. A., de Zeeuw, D., Ivanovich, P., Levey, A. S., Parfrey, P., et al. (2010) · New England Journal of Medicine

Erythropoietin and Anemia TreatmentBiosimilars and Bioanalytical Methods

Cited by 473

A Trial to Evaluate the Effect of the Sodium–Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Morbidity and Mortality in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction (DAPA-HF)

McMurray, J. J. V., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., et al. (2019) · European Journal of Heart Failure

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 433

Cognitive impairment and heart failure: systematic review and meta-analysis

Cannon, J. A., Moffitt, P., Perez-Moreno, A. C., Walters, M. R., Broomfield, N. M., McMurray, J. J. V., & Quinn, T. J. (2017) · Journal of Cardiac Failure

Dementia and Cognitive Impairment ResearchHeart Failure Treatment and Management

Cited by 431

The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting

Roberts, E., Ludman, A. J., Dworzynski, K., Al-Mohammad, A., Cowie, M. R., McMurray, J. J. V., Mant, J., & on behalf of the NICE Guideline Development Group for Acute Heart Failure (2015) · BMJ

Heart Failure Treatment and ManagementCardiac Fibrosis and Remodeling

Cited by 427

A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

Wheeler, D. C., Toto, R. D., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Pecoits-Filho, R., Correa-Rotter, R., et al. (2021) · Kidney International

Chronic Kidney Disease and DiabetesRenal Diseases and Glomerulopathies

Cited by 420

Self-Care Management of Heart Failure: Practical Recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology

Lainscak, M., Blue, L., Clark, A. L., Dahlström, U., Dickstein, K., Ekman, I., McDonagh, T., McMurray, J. J., Ryder, M., Stewart, S., et al. (2011) · European Journal of Heart Failure

Heart Failure Treatment and ManagementCardiac Health and Mental Health

Cited by 405

Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial

Kristensen, S. L., Preiss, D., Jhund, P. S., Squire, I., Cardoso, J. S., Merkely, B., Martinez, F., Starling, R. C., Desai, A. S., Lefkowitz, M. P., et al. (2016) · Circulation Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 359

Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials

Badve, S. V., Bilal, A., Lee, M. M. Y., Sattar, N., Gerstein, H. C., Ruff, C. T., McMurray, J. J. V., Rossing, P., Bakris, G., Mahaffey, K. W., et al. (2025) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 359

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

Ducharme, A., Swedberg, K., Pfeffer, M. A., Cohen-Solal, A., Granger, C. B., Maggioni, A. P., Michelson, E. L., McMurray, J. J. V., Olsson, L., Rouleau, J. L., et al. (2006) · American Heart Journal

Atrial Fibrillation Management and OutcomesHeart Failure Treatment and Management

Cited by 352

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial

Kosiborod, M. N., Jhund, P. S., Docherty, K. F., Diez, M., Petrie, M. C., Verma, S., Nicolau, J. C., Merkely, B., Kitakaze, M., DeMets, D. L., et al. (2020) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 350

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial

Holman, R. R., Coleman, R. L., Chan, J. C. N., Chiasson, J.-L., Feng, H., Ge, J., Gerstein, H. C., Gray, R., Huo, Y., Lang, Z., et al. (2017) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 323

Obesity and cardiovascular disease: An ESC clinical consensus statement

Koskinas, K. C., Van Craenenbroeck, E. M., Antoniades, C., Blüher, M., Gorter, T. M., Hanssen, H., Marx, N., McDonagh, T. A., Mingrone, G., Rosengren, A., et al. (2024) · European Heart Journal

Cardiovascular Function and Risk FactorsObesity, Physical Activity, Diet

Cited by 313